Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | VHL | P40337 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATF1 | P18846 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833337 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL6431541 | 0.83 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL12630133 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL1896996 | 0.80 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL16848164 | 0.79 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL1430802 | 0.78 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL11775192 | 0.77 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL19987400 | 0.77 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL2625562 | 0.76 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A | |
| SCHEMBL22885243 | 0.75 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2ADORA2BADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| CN-101535306-B | Quinuclidine derivatives of (hetero) arylcycloheptylcarboxylic acids as muscarinic receptor antagonists | ASTRAZENECA AB | 2012-09-12 | — | — | CN | disclosed |
| WO-2009138707-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138707-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| CN-101535306-A | Quinuclidine derivatives of (hetero) arylcycloheptylcarboxylic acids as muscarinic receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | CN | disclosed |
| EP-2094694-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008059245-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059245-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | ALDH1A1 3015/4885SMN1; SMN2 3132/4885ADORA2B 3202/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | ALDH1A1 1514/4885SMN1; SMN2 4330/4885ADORA2B 239/4885 |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | ALDH1A1 2159/4885SMN1; SMN2 4780/4885ADORA2B 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.